Mizuho Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $52.00

Apellis Pharmaceuticals (NASDAQ:APLS - Free Report) had its target price cut by Mizuho from $60.00 to $52.00 in a research note released on Monday, Benzinga reports. They currently have a neutral rating on the stock.

APLS has been the topic of a number of other reports. Robert W. Baird reiterated an outperform rating and set a $81.00 price objective on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. Oppenheimer boosted their price target on Apellis Pharmaceuticals from $75.00 to $79.00 and gave the stock an outperform rating in a research report on Tuesday, January 30th. JPMorgan Chase & Co. upped their price objective on Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an overweight rating in a research note on Wednesday, March 6th. Jefferies Financial Group upgraded Apellis Pharmaceuticals from a hold rating to a buy rating and lifted their target price for the company from $68.00 to $80.00 in a research note on Monday, February 5th. Finally, HC Wainwright reissued a buy rating and set a $92.00 price target on shares of Apellis Pharmaceuticals in a research report on Friday. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Apellis Pharmaceuticals currently has an average rating of Moderate Buy and a consensus price target of $77.40.

Apellis Pharmaceuticals Stock Down 4.1 %

NASDAQ APLS traded down $2.02 on Monday, reaching $47.84. 1,400,563 shares of the stock traded hands, compared to its average volume of 1,474,370. Apellis Pharmaceuticals has a 12 month low of $19.83 and a 12 month high of $94.75. The company has a market cap of $5.77 billion, a price-to-earnings ratio of -10.68 and a beta of 0.88. The company has a fifty day moving average price of $57.84 and a 200-day moving average price of $57.53. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.73) EPS for the quarter, meeting the consensus estimate of ($0.73). Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The firm had revenue of $146.38 million for the quarter, compared to analyst estimates of $143.34 million. During the same quarter last year, the firm posted ($1.50) earnings per share. The business's revenue for the quarter was up 545.9% on a year-over-year basis. As a group, research analysts forecast that Apellis Pharmaceuticals will post -1.34 EPS for the current fiscal year.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, CFO Timothy Eugene Sullivan sold 1,431 shares of the firm's stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $67.77, for a total value of $96,978.87. Following the completion of the transaction, the chief financial officer now directly owns 93,338 shares in the company, valued at $6,325,516.26. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CFO Timothy Eugene Sullivan sold 1,431 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $67.77, for a total value of $96,978.87. Following the sale, the chief financial officer now owns 93,338 shares in the company, valued at $6,325,516.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Cedric Francois sold 3,962 shares of the firm's stock in a transaction on Monday, February 12th. The stock was sold at an average price of $67.77, for a total transaction of $268,504.74. Following the transaction, the chief executive officer now directly owns 313,662 shares of the company's stock, valued at approximately $21,256,873.74. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 376,427 shares of company stock worth $23,169,639. 7.50% of the stock is currently owned by insiders.

Institutional Trading of Apellis Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of APLS. First Horizon Advisors Inc. lifted its holdings in Apellis Pharmaceuticals by 69.0% in the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company's stock valued at $25,000 after acquiring an additional 265 shares during the period. Future Financial Wealth Managment LLC purchased a new position in shares of Apellis Pharmaceuticals during the 1st quarter valued at approximately $29,000. Covestor Ltd increased its holdings in shares of Apellis Pharmaceuticals by 564.2% during the 3rd quarter. Covestor Ltd now owns 797 shares of the company's stock valued at $30,000 after purchasing an additional 677 shares in the last quarter. Stephens Consulting LLC acquired a new position in shares of Apellis Pharmaceuticals in the 3rd quarter valued at $38,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Apellis Pharmaceuticals by 29.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,028 shares of the company's stock worth $115,000 after buying an additional 687 shares in the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).